**CONFERENCE SCHEDULE**

**THURSDAY, OCTOBER 26, 2017**

3:00 p.m.-6:00 p.m.
Registration
Broad Street Atrium

---

**FRIDAY, OCTOBER 27, 2017**

7:00 a.m.-5:00 p.m.
Registration
Broad Street Atrium

8:00 a.m.-9:00 a.m.
Continental Breakfast
Terrace Ballroom Foyer

9:00 a.m.-10:30 a.m.
Educational Session: Molecular Tumor Boards
CME-Designated
Terrace Ballroom

**Cochairs:**
Elaine R. Mardis, Nationwide Children's Hospital, Columbus, OH, and Josep Tabernero, Vall d'Hebron University Hospital, Barcelona, Spain

**Leveraging the power of collaboration in a genomics tumor board: None of us is as smart as all of us**
Janessa Laskin, BC Cancer Agency, Vancouver, BC, Canada

**MSK-IMPACT: Tumor/normal sequencing to guide diagnosis, treatment selection, and clinical trial enrollment**
Michael F. Berger, Memorial Sloan Kettering Cancer Center, New York, NY

10:00 a.m.-10:30 a.m.
Molecular tumor boards: Promise and reality
Elena Garralda, Vall d'Hebron University Hospital, Barcelona, Spain

---

2017-2018 SCIENTIFIC CONFERENCES

Presenting the most significant research on cancer etiology, prevention, diagnosis, and treatment

**Prostate Cancer: Advances in Basic, Translational, and Clinical Research**
Cochairs: Johann S. de Bono, Karen E. Knudsen, Peter S. Nelson, and Mark A. Rubin
December 2-5, 2017 • Orlando, FL

**Pediatric Cancer Research: From Basic Science to the Clinic**
Cochairs: Peter C. Adamson, Nada Jabado, and Charles W. M. Roberts
December 3-6, 2017 • Atlanta, GA

**San Antonio Breast Cancer Symposium**
Codirectors: Carlos L. Arteaga, Virginia G. Kaklamani, and C. Kent Osborne
December 5-9, 2017 • San Antonio, TX

**Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic**
Cochairs: Charles M. Rudin and Charles Swanton
January 8-11, 2018 • San Diego, CA

**Obesity and Cancer: Mechanisms Underlying Etiology and Outcomes**
Cochairs: Lewis C. Cantley, Michael N. Pollak, and Elizabeth A. Platz
January 27-30, 2018 • Austin, TX

**Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy**
Cochairs: Hideho Okada, Robyn S. Klein, Ignacio Melero, and Patricia S. Steeg
February 12-15, 2018 • San Diego, CA

**Third AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy**
Cochairs: Todd E. Peterson and David R. Piwnica-Worms
February 14-17, 2018 • San Diego, CA

**Targeting DNA Methylation and Chromatin for Cancer Therapy**
Cochairs: Stephen B. Baylin, Margaret A. Goodell, and Peter A. Jones
March 1-4, 2018 • Atlanta, GA

**AACR Annual Meeting 2018**
Program Committee Chair: Elaine R. Mardis
April 14-18, 2018 • Chicago, IL

**Cancer Dormancy and Residual Disease**
Cochairs: Julio A. Aguirre-Ghiso, Ann F. Chambers, Cyrus M. Ghajar, Christoph A. Klein, and Dorothy A. Sipkins
June 19-22, 2018 • Montréal, QC, Canada

**Malignant Lymphoma: From Basic Science to Clinical Applications**
Chair: Ari M. Melnick
June 22-26, 2018 • Boston, MA

**Sixth JCA-AACR Special Joint Conference on The Latest Advances in Lung Cancer Research: From Basic Science to Therapeutics**
Organizing Committee: Hiroiuki Mano, Seiji Yano, Hiroyoshi Nishikawa (JCA); Alice T. Shaw, Roy S. Herbst, Charles M. Rudin (AACR)
July 10-12, 2018 • Kyoto, Japan

**Intestinal Stem Cells and Colon Cancer: Biology to Therapy**
Cochairs: Anil K. Rustgi, Johanna Bendell, Hans Clevers, Christina Curtis, and Owen Sansom
September 27-30, 2018 • Washington, DC

**Metabolism and Cancer**
Cochairs: Ralph J. Deberardinis, Tak W. Mak, Joshua D. Rabinowitz, and M. Celeste Simon
September 28-October 1, 2018 • New York, NY

---

American Association for Cancer Research
www.AACR.org/Calendar

27
10:30 a.m.-10:50 a.m.
Break
Terrace Ballroom Foyer

10:50 a.m.-12:20 p.m.
Spotlight on Proffered Papers 1
(not eligible for CME credit)
Terrace Ballroom

Cochairs: James L. Gulley, National Cancer Institute,
Bethesda, MD, and Charles Swanton, The Francis Crick
Institute / UCL Cancer Institute, London, United Kingdom

10:50 a.m.-11:00 a.m. Characterization of antitumor
activity of TAS6417, a novel EGFR-
TKI targeting exon 20 insertions*
Shinichi Hasako, Taiho
Pharmaceutical Co., Ltd.,
Tsukuba, Japan

11:00 a.m.-11:10 a.m. EGFR-CD3 bispecific Probody™
therapeutic induces tumor
regressions and increases
maximum tolerated dose
>60-fold in preclinical studies*
Leila Boustanly, CytomX
Therapeutics, Redwood City, CA

11:10 a.m.-11:20 a.m. Neratinib has clinical activity
in HER2-amplified breast cancer
patients with tumors that have
acquired activating mutations
in HER2*
Maurizio Scaltriti, Memorial
Sloan Kettering Cancer Center,
New York, NY

11:20 a.m.-11:30 a.m. Loss of the lysosomal transporter
SLC46A3 is a mechanism for
innate and acquired resistance to
non-cleavable maytansine and
pyrrolobenzodiazepine-based
antibody-drug conjugates*
Krista Kinneer, Medimmune, Inc.,
Gaithersburg, MD

11:30 a.m.-11:40 a.m. AG-120 (ivosidenib), a first-
in-class mutant IDH1 inhibitor,
promotes morphologic
changes and upregulates liver-
specific genes in IDH1 mutant
cholangiocarcinoma*
Yuko Ishii, Agios Pharmaceuticals,
Cambridge, MA

11:40 a.m.-11:50 a.m. Phase 1 study of the EZH2
inhibitor, tazemetostat, in
children with relapsed or
refractory INI1-negative tumors
including rhabdoid tumors,
epithelioid sarcoma, chordoma,
and synovial sarcoma*
Susan N. Chi, Dana-Farber Cancer
Institute, Boston, MA

11:50 a.m.-12:00 p.m. First-in-human, dose-escalation
trial of the combination of
dabrafenib, trametinib, and
navitoclax in patients with BRAF
mutant solid tumors*
Ryan J. Sullivan, Harvard Medical
School, Massachusetts General
Hospital, Boston, MA

12:00 p.m.-12:10 p.m. Preliminary results from a phase 2
proof-of-concept trial of tipifarnib
in tumors with HRAS mutations*
Alan L. Ho, Memorial Sloan Kettering
Cancer Center, New York, NY

12:10 p.m.-12:20 p.m. Durable responses observed in
recurrent high-grade glioma
(rHGG) with Toca 511 and Toca FC
treatment*
Clark Chen, University of Minnesota,
Minneapolis, MN

12:20 p.m.-1:45 p.m.
Lunch on own

*Short talk from proffered paper.

*Short talk from proffered paper.
12:30 p.m.-1:30 p.m.  
AACR Chemistry in Cancer Research (CICR) Town Hall Meeting and Reception  
(not eligible for CME credit)  
Room 121C  
**Cochairs: Melissa M. Vasbinder** (CICR Chair), Ribon Therapeutics, Inc., Lexington, MA, and **Alan G. Olivo** (CICR Steering Committee Member), Genentech, Inc., South San Francisco, CA  
Reception refreshments served courtesy of the CICR Working Group

12:30 p.m.-1:30 p.m.  
AACR Women in Cancer Research (WICR) Professional Advancement Session  
(not eligible for CME credit)  
Room 119  
See page 16

1:50 p.m.-2:00 p.m.  
Welcome and Opening Remarks  
Terrace Ballroom  
**AACR**  
Antoni Ribas, UCLA Medical Center, Los Angeles, CA  
**NCI**  
James L. Gulley, National Cancer Institute, Bethesda, MD  
**EORTC**  
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom

2:00 p.m.-4:10 p.m.  
Keynote Lectures  
CME-Designated  
Terrace Ballroom  
2:00 p.m.-2:02 p.m.  
**Introduction of Lewis C. Cantley**  
Charles Swanton  
2:02 p.m.-2:42 p.m.  
**PI 3-kinase links obesity, insulin resistance, and cancer†**  
Lewis C. Cantley, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY

2:42 p.m.-2:44 p.m.  
**Introduction of Ton Schumacher**  
Antoni Ribas

2:44 p.m.-3:24 p.m.  
**T-cell recognition of human cancer†**  
Ton Schumacher, Netherlands Cancer Institute, Amsterdam, The Netherlands

3:24 p.m.-3:26 p.m.  
**Introduction of Steven A. Rosenberg**  
James L. Gulley

3:26 p.m.-4:06 p.m.  
**Cell transfer immunotherapy targeting unique somatic mutations in cancer†**  
Steven A. Rosenberg, National Cancer Institute, Bethesda, MD

4:10 p.m.-4:30 p.m.  
Break  
Terrace Ballroom Foyer

4:30 p.m.-6:30 p.m.  
Plenary Session 1: Acquired Resistance to Checkpoint Inhibitors  
CME-Designated  
Terrace Ballroom  
**Cochairs: Alberto Bardelli,** University of Turin School of Medicine / IRCCS, Candiolo, Italy, and **Antoni Ribas,** UCLA Medical Center, Los Angeles, CA

4:30 p.m.-5:00 p.m.  
**Resistance to PD-1 blockade in melanoma**  
Antoni Ribas

5:00 p.m.-5:30 p.m.  
**Resistance to PD-1 blockade in MSI-H tumors**  
Luis A. Diaz, Memorial Sloan Kettering Cancer Center, New York, NY

†An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

5:30 p.m.-6:00 p.m.  
Genomic and neoantigen landscape of response and resistance to immune checkpoint blockade  
Victor E. Velculescu, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

6:00 p.m.-6:30 p.m.  
Inactivation of DNA repair to improve immune surveillance  
Alberto Bardelli

6:30 p.m.-7:15 p.m.  
Spotlight on Proffered Papers 2: Immunogenomics and Response to Immunotherapy (not eligible for CME credit)  
Terrace Ballroom  
Chair: Antoni Ribas, UCLA Medical Center, Los Angeles, CA

6:30 p.m.-6:45 p.m.  
Allele-specific HLA loss and immune escape in lung cancer evolution*  
Rachel Rosenthal, University College London, London, United Kingdom

6:45 p.m.-7:00 p.m.  
Immunoediting in untreated mismatch repair deficient colorectal cancer*  
Catherine S. Grasso, University of California, Los Angeles, Los Angeles, CA

7:00 p.m.-7:15 p.m.  
Prediction of clinical outcomes of cancer patients treated with anti-PD-1/PD-L1 using a radiomics-based imaging score of immune infiltrate*  
Roger Sun, Institut Gustave Roussy, Villejuif, France

7:15 p.m.-9:00 p.m.  
Opening Reception  
Terrace Ballroom Foyer

SATURDAY, OCTOBER 28, 2017

7:00 a.m.-5:00 p.m.  
Registration  
Broad Street Atrium

7:00 a.m.-8:00 a.m.  
Continental Breakfast  
Terrace Ballroom Foyer

8:00 a.m.-10:00 a.m.  
Plenary Session 2: Defining and Targeting Cancer Neoepitopes  
CME-Designated  
Terrace Ballroom  
Cochairs: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, MA, and Eliezer M. Van Allen, Dana-Farber Cancer Institute, Boston, MA

8:00 a.m.-8:30 a.m.  
Building personal cancer vaccines  
Catherine J. Wu

8:00 a.m.-9:00 a.m.  
Immunopeptidomics: Accelerating the development of personalized cancer immunotherapy†  
Michal Bassani-Sternberg, UNIL/CHUV Ludwig Cancer Research Center, Epalinges, Switzerland

9:00 a.m.-9:30 a.m.  
Insertion-and-deletion-derived tumor-specific neoantigens and the immunogenic phenotype: A pan-cancer analysis  
Samra Turajlic, The Francis Crick Institute and the Royal Marsden Hospital, London, United Kingdom

9:30 a.m.-10:00 a.m.  
Leveraging clinical genomics for candidate neoantigen discovery  
Eliezer M. Van Allen

7:00 p.m.-7:15 p.m.  
Genomic and neoantigen landscape of response and resistance to immune checkpoint blockade  
Victor E. Velculescu, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD

6:00 p.m.-6:30 p.m.  
Inactivation of DNA repair to improve immune surveillance  
Alberto Bardelli

6:30 p.m.-7:15 p.m.  
Spotlight on Proffered Papers 2: Immunogenomics and Response to Immunotherapy (not eligible for CME credit)  
Terrace Ballroom  
Chair: Antoni Ribas, UCLA Medical Center, Los Angeles, CA

6:30 p.m.-6:45 p.m.  
Allele-specific HLA loss and immune escape in lung cancer evolution*  
Rachel Rosenthal, University College London, London, United Kingdom

6:45 p.m.-7:00 p.m.  
Immunoediting in untreated mismatch repair deficient colorectal cancer*  
Catherine S. Grasso, University of California, Los Angeles, Los Angeles, CA

7:00 p.m.-7:15 p.m.  
Prediction of clinical outcomes of cancer patients treated with anti-PD-1/PD-L1 using a radiomics-based imaging score of immune infiltrate*  
Roger Sun, Institut Gustave Roussy, Villejuif, France

7:15 p.m.-9:00 p.m.  
Opening Reception  
Terrace Ballroom Foyer

*Short talk from proffered paper.

†An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
10:00 a.m.-10:20 a.m.
Break
Terrace Ballroom Foyer

10:20 a.m.-12:20 p.m.
Plenary Session 3: Challenges and Opportunities of Genomic-Based Clinical Trials
CME-Designated
Terrace Ballroom

Cochairs: José Baselga, Memorial Sloan Kettering Cancer Center, New York, NY, and James L. Gulley, National Cancer Institute, Bethesda, MD

10:20 a.m.-10:45 a.m. NCI-MATCH: A new paradigm in the era of genomic oncology
Alice P. Chen, National Cancer Institute, Bethesda, MD (not eligible for CME credit)

10:45 a.m.-11:10 a.m. Navigating the known and unknown challenges in the development of a selective NTRK inhibitor: The larotrectinib story
Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA (not eligible for CME credit)

11:10 a.m.-11:35 a.m. The National Lung Matrix Trial (NLMT): Challenges and opportunities†
Gary Middleton, University of Birmingham, Birmingham, United Kingdom

11:35 a.m.-12:00 p.m. Implementing genomic-driven basket clinical trials
José Baselga

12:00 p.m.-12:15 p.m. Transcriptomic analysis of patient-derived xenografts reveals heterogeneity in human and mouse stroma/immune compartments*
Henry Qixiang Li, Crown Bioscience, Inc., Beijing, China (not eligible for CME credit)

12:30 p.m.-4:00 p.m.
Poster Session A
(not eligible for CME credit)
Hall E

Animal Models
Apoptosis, Necrosis, and Autophagy
Bioinformatics
Biomarkers
Cancer Stem Cells
Cell Cycle Regulators
Cellular Responses to Therapy
Chemistry
Chemoprevention
Clinical Trials
DNA Repair and Modulation
Drug Delivery
Drug Design
Drug Resistance and Modifiers
Drug Screening
EGFR/Her2
Epigenetic Regulation of Tumor Immunity
Epigenetic Targets
Genomics, Proteomics, and Target Discovery
Hormonal Agents and Therapy
Immune Checkpoints
Immune Mechanisms Invoked by Radiation Therapy
In Vitro and In Vivo Models for Targets

*Short talk from proffered paper.
†An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
12:30 p.m.-5:30 p.m.
Exhibit Show
(not eligible for CME credit)
Hall E

4:30 p.m.-6:00 p.m.
Concurrent Session 1: Aneuploidy as a Driver of Cancer Evolution
CME-Designated
Room 115
Cochairs: Charles Swanton, The Francis Crick Institute / UCL Cancer Institute, London, United Kingdom, and Samuel F. Bakhour, Memorial Sloan Kettering Cancer Center, New York, NY

4:30 p.m.-4:55 p.m.  
**Job's dilemma for the genome: Why bad things happen to good chromosomes**
David Pellman, Dana-Farber Cancer Institute, Boston, MA

4:55 p.m.-5:20 p.m.  
**Chromosomal instability as a driver of tumor metastasis**†
Samuel F. Bakhour

5:20 p.m.-5:45 p.m.  
**Mechanisms of aneuploidy-driven tumorigenesis**
Stephen J. Elledge, Harvard Medical School, Boston, MA

5:45 p.m.-6:00 p.m.  
**Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures*** 
Thomas G. Graeber, University of California, Los Angeles, Los Angeles, CA  
(not eligible for CME credit)

4:30 p.m.-6:00 p.m.
Concurrent Session 2: CNS Penetration of Drugs
CME-Designated
Room 118
Cochairs: E.G. Elisabeth de Vries, University Medical Center Groningen, Groningen, The Netherlands, and Patricia S. Steeg, National Cancer Institute, Bethesda, MD

4:30 p.m.-5:00 p.m.  
**Structure of the blood-tumor barrier and potential ways to overcome it**
Patricia S. Steeg

5:00 p.m.-5:30 p.m.  
**Immunotherapy for central nervous system cancers**†
John H. Sampson, Duke University Medical Center, Durham, NC

5:30 p.m.-6:00 p.m.  
**Cancer drug distribution in the brain: PET imaging as a tool**
E.G. Elisabeth de Vries

4:30 p.m.-6:00 p.m.
Concurrent Session 3: Mechanistic Principles of Cancer Cells
CME-Designated
Room 120
Cochairs: Andrea Califano, Columbia University, New York, NY, and Gerard I. Evan, University of Cambridge, Cambridge, United Kingdom

4:30 p.m.-5:00 p.m.  
**Systematic elucidation and pharmacologic targeting of mechanistic tumor dependencies**
Andrea Califano

5:00 p.m.-6:00 p.m.  
**Genetics and mechanisms of chemotherapy resistance in acute lymphoblastic leukemia**
Adolfo Ferrando, Columbia University, New York, NY

5:30 p.m.-6:00 p.m.  
**How Ras and Myc cooperate to drive cancers**
Gerard I. Evan

*Short talk from proffered paper.
†An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

4:30 p.m.-6:00 p.m.  Concurrent Session 4: Cancer Metabolism
CME-Designated
Terrace Ballroom

Cochairs: Dimitrios Anastasiou, Harvard Medical School, Boston, MA, and W. Marston Linehan, National Cancer Institute, Bethesda, MD

4:30 p.m.-5:00 p.m.  Targeting metabolic vulnerabilities in cancer
Dimitrios Anastasiou

5:00 p.m.-5:30 p.m.  Title to be announced
Angela T. Alistar, Morristown Medical Center, Morristown, NJ

5:30 p.m.-6:00 p.m.  Targeting the metabolic basis of kidney cancer†
W. Marston Linehan

8:30 a.m.-9:00 a.m.  Analysis and therapeutic targeting of Hodgkin lymphoma tumor microenvironment
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

9:00 a.m.-9:30 a.m.  Virus mimicry and pattern recognition receptor activation by exosomes in the tumor microenvironment
Andy J. Minn, University of Pennsylvania, Philadelphia, PA

9:30 a.m.-10:00 a.m.  Comprehensive enumeration of infiltrating immune cells in triple-negative breast cancer using multiplexed ion beam imaging
Michael Angelo

10:00 a.m.-10:20 a.m.  Break
Terrace Ballroom Foyer

10:20 a.m.-12:20 p.m.  Plenary Session 5: Epigenetics
CME-Designated
Terrace Ballroom

Cochairs: Howard Y. Chang, Stanford University, Stanford, CA, and Louis M. Staudt, National Cancer Institute, Bethesda, MD

10:20 a.m.-10:50 a.m.  Personal regulome navigation†
Howard Y. Chang

10:50 a.m.-11:20 a.m.  Transcriptional addiction in cancer
James E. Bradner, Novartis Institutes for BioMedical Research, Cambridge, MA (not eligible for CME credit)

11:20 a.m.-11:50 a.m.  Histone-3 K27M mutant diffuse midline gliomas of childhood: Epigenetic pathogenesis and therapeutic opportunities†
Michelle Monje, Stanford University School of Medicine, Stanford, CA

SUNDAY, OCTOBER 29, 2017

7:00 a.m.-5:00 p.m.  Registration
Broad Street Atrium

7:00 a.m.-8:00 a.m.  Continental Breakfast
Terrace Ballroom Foyer

8:00 a.m.-10:00 a.m.  Plenary Session 4: Deciphering the Complexity of the Tumor Microenvironment
CME-Designated
Terrace Ballroom

Cochairs: Michael Angelo, Stanford University School of Medicine, Stanford, CA, and Erik Sahai, The Francis Crick Institute, London, United Kingdom

8:00 a.m.-8:30 a.m.  Imaging therapy failure and cancer invasion
Erik Sahai

8:00 a.m.-9:00 a.m.  Analysis and therapeutic targeting of Hodgkin lymphoma tumor microenvironment
Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA

9:00 a.m.-9:30 a.m.  Virus mimicry and pattern recognition receptor activation by exosomes in the tumor microenvironment
Andy J. Minn, University of Pennsylvania, Philadelphia, PA

9:30 a.m.-10:00 a.m.  Comprehensive enumeration of infiltrating immune cells in triple-negative breast cancer using multiplexed ion beam imaging
Michael Angelo

10:00 a.m.-10:20 a.m.  Break
Terrace Ballroom Foyer

10:20 a.m.-12:20 p.m.  Plenary Session 5: Epigenetics
CME-Designated
Terrace Ballroom

Cochairs: Howard Y. Chang, Stanford University, Stanford, CA, and Louis M. Staudt, National Cancer Institute, Bethesda, MD

10:20 a.m.-10:50 a.m.  Personal regulome navigation†
Howard Y. Chang

10:50 a.m.-11:20 a.m.  Transcriptional addiction in cancer
James E. Bradner, Novartis Institutes for BioMedical Research, Cambridge, MA (not eligible for CME credit)

11:20 a.m.-11:50 a.m.  Histone-3 K27M mutant diffuse midline gliomas of childhood: Epigenetic pathogenesis and therapeutic opportunities†
Michelle Monje, Stanford University School of Medicine, Stanford, CA

† An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.

† An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
11:50 a.m.-12:20 p.m. **Targeting essential transcriptional networks in lymphoma**  
Louis M. Staudt

12:30 p.m.-4:00 p.m. **Poster Session B**  
*(not eligible for CME credit)*  
Hall E

**Immune Modulators**
**Immune Monitoring/Clinical Correlates**
**Immune Response to Therapies**
**MAPK Pathways**
**Metabolism**
**Metastasis and Invasion**
**Monoclonal Antibodies**
**Natural Products**
**New Molecular Targets**
**Novel Assay Technology**
**Other Topics**
**Pharmacogenetics, Pharmacogenomics, and Therapeutic Response**
**Pharmacokinetics and Pharmacodynamics**
**Radiotherapeutics**
**RNA and RNA-Based Technologies and Therapies**
**Signal Transduction Modulators**
**Target Identification and Validation**
**Therapeutic Agents: Biologic**
**Therapeutic Agents: Other Topics**
**Therapeutic Agents: Small-Molecule Kinase Inhibitors**
**Topoisomerase Inhibitors**
**Tubulin-Interacting Agents**
**Tumor Immunology Targets**
**Tumor Microenvironment**
**Tumor Suppressors**

12:30 p.m.-5:30 p.m. **Exhibit Show**  
*(not eligible for CME credit)*  
Hall E

4:30 p.m.-6:00 p.m. **Concurrent Session 5: DNA Damage and Repair**  
*CME-Designated*

**Room 115**

**Cochairs:** Serena Nik-Zainal, Wellcome Trust Sanger Institute, Cambridge, United Kingdom, and Yves G. Pommier, NCI-CCR, Bethesda, MD

4:30 p.m.-5:00 p.m. **DNA damage signatures and practical use**
Serena Nik-Zainal

5:00 p.m.-5:30 p.m. **Novel mechanisms of PARP inhibitor resistance**
Alan D. D’Andrea, Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Boston, MA

5:30 p.m.-6:00 p.m. **Precision therapeutics with DNA-damaging agents**
Yves G. Pommier

4:30 p.m.-6:00 p.m. **Concurrent Session 6: Metastatic Microenvironment**  
*CME-Designated*

**Room 118**

**Cochairs:** Yibin Kang, Princeton University, Princeton, NJ, and Ilaria Malanchi, The Francis Crick Institute, London, United Kingdom

4:30 p.m.-4:55 p.m. **Targeting stromal niche for the treatment of bone metastasis**
Yibin Kang

4:55 p.m.-5:20 p.m. **Precision medicine for melanoma**
Richard M. Marais, Cancer Research UK Manchester Institute, Manchester, United Kingdom

*An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.*
5:20 p.m.-5:45 p.m. The teamwork of neutrophils and cancer
Ilaria Malanchi

5:45 p.m.-6:00 p.m. Heterogeneity in androgen receptor and IL-1beta expression by prostate cancer cells in skeletal metastases*
Asurayya A. Worrede-Mahdi, Drexel University College of Medicine, Philadelphia, PA (not eligible for CME credit)

4:30 p.m.-6:00 p.m.
Concurrent Session 8: Tracking Cancer in the Blood
CME-Designated
Terrace Ballroom

Cochairs: Maximilian Diehn, Stanford University, Stanford, CA, and Caroline Dive, Cancer Research UK Manchester Institute, Manchester, United Kingdom

4:30 p.m.-5:00 p.m. Circulating tumor DNA analysis for personalized cancer detection and monitoring
Maximilian Diehn

5:00 p.m.-5:30 p.m. Molecular detection and characterization of circulating tumor cells†
Daniel A. Haber, Massachusetts General Hospital, Charlestown, MA

5:30 p.m.-6:00 p.m. Liquid biopsies for the management of cancer patient treatment and for the early detection of cancers†
Caroline Dive

4:30 p.m.-6:00 p.m.
Concurrent Session 7: The Role of Nonmutated Genes in Cancer Biology
CME-Designated
Room 120

Cochairs: Thomas Brabletz, University of Erlangen, Erlangen, Germany, and Claudia M. Palena, NCI-CCR, Bethesda, MD

4:30 p.m.-5:00 p.m. Cellular plasticity in cancer: Driving force and therapeutic target†
Thomas Brabletz

5:00 p.m.-5:30 p.m. Epigenetics: A gatekeeper to DNA amplification
Johnathan R. Whetstine, Harvard Medical School, Charlestown, MA

5:30 p.m.-6:00 p.m. Brachyury and the interleukin-8 axis in tumor progression†
Claudia M. Palena

MONDAY, OCTOBER 30, 2017

7:00 a.m.-12:00 p.m.
Registration
Broad Street Atrium

7:00 a.m.-8:00 a.m.
Continental Breakfast
Terrace Ballroom Foyer

*Short talk from proffered paper.
†An extended abstract for this presentation is available in the online Proceedings or in the Program Guide app.
CONFERENCE SCHEDULE

8:00 a.m.-10:00 a.m.
Plenary Session 6: CAR-T Therapy
CME-Designated
Terrace Ballroom

Cochairs: Martin Pule, Autolus, London, United Kingdom, and Michel Sadelain, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 a.m.-8:30 a.m.  CAR therapy beyond the CD19 paradigm
Michel Sadelain

8:30 a.m.-9:00 a.m.  Improving remission durability after CAR T-cell therapy for ALL
Terry J. Fry, National Cancer Institute, Bethesda, MD

9:00 a.m.-9:30 a.m.  Title to be announced
Martin Pule

9:30 a.m.-10:00 a.m.  Engineering human T cells with nonviral genome targeting
Theodore Roth, University of California, San Francisco, San Francisco, CA

10:00 a.m.-10:20 a.m.
Break
Terrace Ballroom Foyer

10:20 a.m.-12:20 p.m.
Plenary Session 7: Drugging the Undruggable / Historically Challenging Targets
(not eligible for CME credit)
Terrace Ballroom

Cochairs: Neal Rosen, Memorial Sloan Kettering Cancer Center, New York, NY, and Jeffrey A. Engelman, Novartis, Cambridge, MA

10:20 a.m.-10:50 a.m.  PROTAC-mediated protein degradation: A chemical equivalent of CRISPR
Craig M. Crews, Yale University, New Haven, CT

10:50 a.m.-11:20 a.m.  Block the exits—ABL001 enables dual targeting of BCR-ABL
Andrew Wylie, Novartis, Cambridge, MA

11:20 a.m.-11:50 a.m.  Title to be announced
Neal Rosen

11:50 a.m.-12:20 p.m.  Title to be announced
Jeffrey A. Engelman

12:20 p.m.-12:30 p.m.
Closing Remarks
Terrace Ballroom

AACR
Antoni Ribas, UCLA Medical Center, Los Angeles, CA

NCI
James L. Gulley, National Cancer Institute, Bethesda, MD

EORTC
Charles Swanton, The Francis Crick Institute and UCL Cancer Institute, London, United Kingdom